Patterns of practice in the management of prostate cancer: Results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000

BJU International

Volumn 97, Issue 5, 2006, Pages 975-980

  Chong, Colin C W ^a,e   Austen, Lynette ^b   Kneebone, Andrew ^a,c,f   Lalak, Andre ^d   Jalaludin, Bin ^e  

^a CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

^b CANBERRA HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ANZAC Research Institute   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f LIVERPOOL HOSPITAL   (Australia)

Author keywords

Clinical practice guidelines; Patterns of practice; Prostate cancer; Surveys; Treatment recommendations

Indexed keywords

GONADORELIN AGONIST; HORMONE;

ADULT; ADVANCED CANCER; ARTICLE; AUSTRALIA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; LYMPH NODE METASTASIS; MEDICAL SPECIALIST; MULTIMODALITY CANCER THERAPY; NEW ZEALAND; ONCOLOGY; ORCHIECTOMY; PELVIS LYMPH NODE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PUBLICATION; QUESTIONNAIRE; SURGICAL TECHNIQUE; TIME SERIES ANALYSIS; UROLOGY;

ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; AUSTRALIA; BONE NEOPLASMS; HEALTH CARE SURVEYS; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REFERRAL AND CONSULTATION;

EID: 33645749109     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06065.x     Document Type: Article

References (29)

1. Partin AW Kattan MW Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 277 1445 51
2. Partin AW Mangold LA Lamm DM Walsch PC Epstein JI Pearson JD. Prostate Cancer. The Partin Tables 2004. 13 October 2004. Available from: http://urology.jhu.edu/prostate/partintables.php. Accessed November 2005
3. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997 37 1035 41
4. Stapleton AM Cuncins-Hearn A Pinnock C. Attitudes to evidence-based practice in urology: results of a survey. ANZ J Surg 2001 71 297 300
5. Asch DA Jedrziewski MK Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997 50 1129 36
6. Kellerman SE Herold J. Physician response to surveys. A review of the literature. Am J Prev Med 2001 20 61 7
7. Australian Health Technology Advisory Committee. Prostate cancer screening. Canberra Australian Government Publishing Service 1996
8. Mettlin CJ Murphy GP Rosenthal DS Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998 83 1679 84
9. Abrahamsson PA. The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for. Eur Urol 1996 29 Suppl. 2 27 30
10. Kattan MW Cowen ME Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997 12 299 305
11. Pilepich MV Krall JM al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma. a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995 45 616 23
12. Bolla M Gonzalez D Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997 337 295 300
13. D'Amico AV Schultz D Loffredo M et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000 284 1280 3
14. D'Amico AV Manola J Loffredo M Renshaw AA DellaCroce A Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004 292 821 7
15. Zelefsky MJ Leibel SA Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998 41 491 500
16. Sternberg CN. Hormonal therapy and radiation therapy in the treatment of locally advanced prostate cancer. Mol Urol 1999 3 227 30
17. Messing EM Manola J Sarosdy M Wilding G Crawford ED Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 1781 8
18. Pilepich MV Caplan R Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997 15 1013 21
19. Boccon-Gibod L Bertaccini A Bono AV et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003 57 187 94
20. Duchesne GM Millar JL Moraga V Rosenthal M Royce P Snow R. What to do for prostate cancer patients with a rising PSA? - A survey of Australian practice. Int J Radiat Oncol Biol Phys 2003 55 986 91
21. Daniell HW Dunn SR Ferguson DW Lomas G Niazi Z Sratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000 163 181 6
22. Stoch SA Parker RA Chen L et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001 86 2787 91
23. Lund BC Bever-Stille KA Perry PJ. Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 1999 19 951 6
24. Wiegel T Bottke D Willich N. Phase III results of adjuvant radiotherapy (RT) versus 'wait and see' (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02 / AUO AP 09/95). American Society of Clinical Oncology (ASCO) Annual Meeting 2005 May 13-17 Orlando, Florida (Abstract no: 4513)
25. Bolla M Van Poppel H Van Cangh P et al. Postoperative radiotherapy after radical prostatectomy improves progression-free survival in pT3N0 prostate cancer. (EORTC 22911) Int J Radiat Oncol Biol Phys 2004 60 Suppl. 1 S186
26. Thompson IM Tangen C Miller G et al. Adjuvant radiotherapy for pathologic T3 prostate cancer. Results of a Randomized, Prospective Clinical 24 Trial with Metastasis-Free Survival Endpoint. American Urological Association Annual Meeting 2005 May 21-26 San Antonio, Texas. (Abstract no: 1665)
27. Pound CR Partin AW Eisenberger MA Chan DW Pearson JD Waisch PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 1591 7
28. D'Amico AV Moul J Carroll PR Sun L Lubeck D Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004 172 S42 7
29. Carroll PR Chan JM D'Amico AV et al. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol 2004 172 S3 5